As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence
of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of …

This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document …

Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic
syndrome. It represents a wide spectrum of histopathological abnormalities ranging from …

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

Background & Aims Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver
damage and is characterized by steatosis. Genetic factors increase risk for progressive …

Non-alcoholic steatohepatitis (NASH) is part of the spectrum of non-alcoholic fatty liver
disease (NAFLD) that leads to progressive liver disease and presents a growing challenge …

An improved understanding of non-alcoholic fatty liver disease epidemiology would lead to
identification of individuals at high risk of developing chronic liver disease and extra-hepatic …

Non-alcoholic fatty liver disease (NAFLD) has become one of the most prominent forms of
chronic liver disease worldwide, reflecting the epidemic of global obesity. Those with the …

Excess hepatic storage of triglycerides is considered a benign condition, but nonalcoholic
steatohepatitis (NASH) may progress to fibrosis and promote atherosclerosis. Carriers of the …

Background & Aims Excess hepatic free cholesterol contributes to the pathogenesis of non-
alcoholic steatohepatitis, and statins reduce cholesterol synthesis. Aim of this study was to …